Xenetic Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Xenetic Biosciences

13/11/2024 14:27

* Xenetic Biosciences Inc  XBIO.OQ  reported a quarterly
adjusted
loss of 28 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -69 cents.  The lone analyst forecast for the
quarter was for a loss of 14 cents per share. 
    * Revenue rose 0.5% to $614.24 thousand from a year ago;
analysts
expected $750.00 thousand. 
    * Xenetic Biosciences Inc's reported EPS for the quarter was
a
loss of 28 cents​.
    * The company reported a quarterly loss of $436.67 thousand.
    * Xenetic Biosciences Inc shares had fallen by 4.4% this
quarter and gained 19.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

This summary was machine generated from LSEG data November 13 at
02:26 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.14          -0.28          Missed
 Jun. 30 2024      -0.83          -0.83          Met
 Mar. 31 2024      -0.79          -0.78          Beat
 Dec. 31 2023      -0.87          -0.77          Beat